Russell Sion, Butt Salman, Vohra Hunaid A
Department of Cardiac Surgery/Cardiovascular Sciences, Bristol Heart Institute, University of Bristol, Bristol, UK.
Department of Perfusion Sciences, St George's Hospital, London, UK.
Perfusion. 2022 Oct;37(7):668-674. doi: 10.1177/02676591211012554. Epub 2021 Jun 3.
Cardioplegic solutions are used in cardiac surgery to achieve controlled cardiac arrest during operations, making surgery safer. Cardioplegia can either be blood or crystalloid based, with perceived pros and cons of each type. Whilst it is known that cardioplegia causes cardiac arrest, there is debate over which cardioplegic solution provides the highest degree of myocardial protection during arrest. Myocardial damage is measured post-operatively by biomarkers such as serum TnT, TnI or CK-MB. It is known that the outcomes of minimally invasive valve surgery are comparable to full sternotomy valve operations. Despite there being a wide diversity in use of different cardioplegic solutions across the world, this comprehensive literature review found no superiority of one cardioplegic solution over the other for myocardial protection during minimally invasive valve procedures.
心脏停搏液用于心脏手术中,以在手术期间实现可控的心脏骤停,从而使手术更安全。心脏停搏液可以是基于血液的,也可以是基于晶体的,每种类型都有其各自的优缺点。虽然已知心脏停搏液会导致心脏骤停,但对于哪种心脏停搏液在心脏停搏期间能提供最高程度的心肌保护存在争议。术后通过生物标志物如血清肌钙蛋白T(TnT)、肌钙蛋白I(TnI)或肌酸激酶同工酶(CK-MB)来测量心肌损伤。已知微创瓣膜手术的结果与全胸骨切开瓣膜手术相当。尽管世界各地使用的不同心脏停搏液种类繁多,但这项全面的文献综述发现,在微创瓣膜手术中,一种心脏停搏液在心肌保护方面并不优于另一种。